Arcturus Shares Drop on ‘Mixed’ Results for Inhaled mRNA Therapy in Cystic Fibrosis
Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug Arcturus Therapeutics’ inhaled mRNA therapy ARCT-032 failed to show meaningful improvements in lung function in a Phase II trial…
MERS-CoV Added to WHO BioHub to Boost Research and Preparedness
MERS-CoV virus isolate added to the WHO BioHub System, enabling further research and pandemic preparedness Through the BioHub, countries can voluntarily share and request biological materials with epidemic or pandemic…
Biotech Markets Show Signs of Recovery—but Analysts Warn It’s Too Soon to Celebrate
Biotech Markets Turn Positive but Experts Say Don’t Call It a Comeback—Yet M&A is back, the S&P XBI is rising again, a biotech pulled off an IPO and positive data…
Leadership Lab: Spotting Early Signs of Employee Turnover in Biopharma
Leadership Lab: How To Spot When Employees Are About To Walk Away Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework that…
WuXi Biologics Receives 2025 Global Customer Value Leadership Award from Frost & Sullivan
Recognition highlights WuXi Biologics’ commitment to delivering exceptional value and innovative solutions to its global clients. WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today…
IDWeek 2025: Shionogi Highlights Data Supporting Cefiderocol’s sRole in Tough-to-Treat Infections
New findings underscore Cefiderocol’s efficacy and reliability in managing complex, multidrug-resistant bacterial infections. Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presents…
Replimune Shares Surge After FDA Resubmission for Advanced Melanoma Therapy
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future.…
Roche’s Gazyva Secures FDA Approval for Lupus, Marking Expansion Beyond Cancer
The FDA approval marks Gazyva’s first non-oncology indication, expanding Roche’s presence into autoimmune disease treatment. The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple…
Counteracting Complacency in Multiple Myeloma: The Fight Is Far from Over
Despite major therapeutic advances, patients with multiple myeloma continue to face relapse and resistance—demanding renewed focus and innovation. Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but…
Hansoh Pharma Presents Phase 2 Data on HS-20089 for Platinum-Resistant Ovarian Cancer at ESMO 2025
The investigational B7-H4–targeted antibody–drug conjugate HS-20089 demonstrates encouraging efficacy and manageable safety in patients with platinum-resistant ovarian cancer. Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced positive phase…
Fiji Achieves Milestone as the 26th Country to Eliminate Trachoma as a Public Health Concern
The World Health Organization confirms Fiji has eliminated trachoma as a public health problem, marking a major step toward global eye health goals. In a landmark public health achievement, Fiji…
Novartis Kisqali® 5-Year Data Show 28% Reduced Recurrence Risk in Early Breast Cancer
Novartis Kisqali® Shows Sustained Five-Year Benefit in Broad Early Breast Cancer Population Novartis today released results from the five-year analysis of the pivotal Phase III NATALEE trial, confirming the long-term…